Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Y-Mabs Therapeutics Inc (NQ: YMAB )

8.390 +0.220 (+2.69%)
Streaming Delayed Price Updated: 12:52 PM EDT, Jun 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 82,750
Open 8.020
Bid (Size) 8.350 (5)
Ask (Size) 8.420 (7)
Prev. Close 8.170
Today's Range 7.920 - 8.390
52wk Range 2.700 - 20.48
Shares Outstanding 43,677,767
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
B of A Securities Maintains Neutral Rating for Y-mAbs Therapeutics: Here's What You Need To Know
 
Via Benzinga
Analyst Upgrades Y-mAbs On Bullish Danyelza Sales Outlook, Improved Visibility
Wedbush has upgraded Y-mAbs Therapeutics Inc (NASDAQ: YMAB)to Outperform from Neutral, with a  
Via Benzinga

Performance

YTD
+74.43%
+74.43%
1 Month
+21.42%
+21.42%
3 Month
+106.65%
+106.65%
6 Month
+90.25%
+90.25%
1 Year
-34.81%
-34.81%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023
Via Benzinga
Earnings Scheduled For May 8, 2023
Via Benzinga
Preview: Y-mAbs Therapeutics's Earnings
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
Via Benzinga
Earnings Outlook For Y-mAbs Therapeutics
Via Benzinga
Crude Oil Rises 1.5%; Checkpoint Therapeutics Shares Slide
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Quarterly Gain Still Eludes Dow Despite Triple-Digit Lead
Via Talk Markets
Nasdaq Surges Over 100 Points; G Medical Innovations Shares Plunge
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Chicken Soup for the Soul Entertainment Shares Are Trading Lower By 30%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For March 30, 2023
Via Benzinga
YMAB FINAL DEADLINE TOMORROW: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 20 Deadline in Securities Class Action - YMAB
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Y-MABS THERAPEUTICS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB
From Kahn Swick & Foti, LLC
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
YMAB FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 20 Deadline in Securities Class Action – YMAB
From The Rosen Law Firm PA
Via GlobeNewswire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)
From The Law Offices of Frank R. Cruz
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Fate, Sotera, and Argo and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.